Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.64 |
| ▸ | PDE4C | Q08493 | 20/20 | 0.64 |
| ▸ | PDE4A | P27815 | 14/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1583109 | 0.92 | PDE4B (0.66) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL5423831 | 0.90 | PDE4B (0.55) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL825653 | 0.89 | PDE4B (0.53) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL825644 | 0.89 | PDE4B (0.52) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL6870187 | 0.88 | PDE4B (0.51) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL825879 | 0.87 | PDE4B (0.53) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL5191733 | 0.87 | PDE4B (0.51) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL10325021 | 0.87 | PDE4B (0.54) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL25205204 | 0.86 | PDE4B (0.69) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL825619 | 0.86 | PDE4B (0.69) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1126839-A4 | SUBSTITUTED PHENETHYLSULFONES AND METHOD OF REDUCING TNF ALPHA LEVELS | CELGENE CORP (US) | 2004-10-27 | — | — | EP | claimed |
| EP-1126839-A1 | SUBSTITUTED PHENETHYLSULFONES AND METHOD OF REDUCING TNF ALPHA LEVELS | CELGENE CORPORATION (US) | 2001-08-29 | — | — | EP | claimed |
| WO-2000025777-A1 | SUBSTITUTED PHENETHYLSULFONES AND METHOD OF REDUCING TNFαLEVELS | CELGENE CORPORATION (US) | 2000-05-11 | — | — | WO | claimed |
| EP-1556033-A4 | METHODS AND COMPOSITIONS USING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORP (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1556033-A1 | METHODS AND COMPOSITIONS USING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORPORATION (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1538913-A2 | MODULATION OF STEM AND PROGENITOR CELL DIFFERENTIATION, ASSAYS, AND USES THEREOF | CELGENE CORPORATION (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2003097040-A1 | METHODS AND COMPOSITIONS USING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003087333-A2 | MODULATION OF STEM AND PROGENITOR CELL DIFFERENTIATION, ASSAYS, AND USES THEREOF | CELGENE CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |